```html

Respiratory Distress Syndrome (RDS)

Overview

Respiratory distress syndrome (RDS) is a condition in which the lungs cannot provide enough oxygen to meet the body’s needs. The term is most commonly used to describe two distinct clinical entities:

• Neonatal RDS (also called hyaline membrane disease) – primarily affects premature infants whose lungs lack sufficient surfactant.
• Adult respiratory distress syndrome (ARDS) – a severe inflammatory lung injury that can follow infection, trauma, or other systemic insults.

Both share the hallmark of rapid breathing and low oxygen levels, but they differ in cause, age group, and management.

Who it affects

• Neonatal RDS: Premature infants born before 34 weeks gestation; incidence is ~1 % of all live births in the United States but up to 10 % in infants born <28 weeks <sup>1</sup>.
• Adult RDS/ARDS: Adults of any age after severe illness or injury; occurs in ~10 % of patients on mechanical ventilation in intensive care units worldwide <sup>2</sup>.

Prevalence & Impact

Worldwide, ARDS accounts for an estimated 3 million cases annually, with a mortality rate ranging from 30 % to 45 % despite modern intensive‑care support <sup>3</sup>. Neonatal RDS remains a leading cause of early infant mortality in low‑resource settings, though surfactant therapy and antenatal steroids have reduced mortality by >50 % in high‑income countries <sup>4</sup>.

---

Symptoms

Symptoms can develop rapidly; recognize them early.

Neonatal RDS

• Rapid, shallow breathing (tachypnea) – >60 breaths/min in term infants, >80 breaths/min in preterms.
• Grunting sound during exhalation – a reflex to keep alveoli open.
• Flaring of nostrils and use of accessory muscles.
• Chest retractions (skin pulled in between ribs or under the breastbone).
• Blue‑tinted skin (cyanosis) especially around lips and fingertips.
• Low oxygen saturation on pulse‑oximetry (<90 %).

Adult RDS/ARDS

• Severe shortness of breath that worsens with activity or even at rest.
• Rapid breathing (tachypnea) >30 breaths/min.
• Low blood oxygen (PaO₂/FiO₂ ratio < 300 mmHg).
• Diffuse crackles heard with a stethoscope.
• Chest pain or discomfort from the effort of breathing.
• Fatigue, confusion, or worsening mental status due to hypoxia.
• Fever, chills, or signs of underlying infection (common triggers).

---

Causes and Risk Factors

Neonatal RDS

• Surfactant deficiency – immature type II alveolar cells cannot produce enough surfactant, a substance that reduces surface tension.
• Prematurity – the earlier the birth, the lower the surfactant levels.
• Maternal diabetes – high insulin levels can delay surfactant production.
• Male sex – boys are about 1.5 times more likely to develop RDS.
• Cesarean delivery without labor – lack of hormonal surge that stimulates surfactant release.

Adult RDS/ARDS

• Severe infection – pneumonia, sepsis, COVID‑19 are the most common precipitants.
• Trauma – lung contusion, multiple fractures, smoke inhalation.
• Aspiration of gastric contents.
• Pancreatitis or massive blood transfusion.
• Inhalation of toxic gases or chemicals.
• Pre‑existing lung disease – COPD, interstitial lung disease, or chronic heart failure.
• Age >65 years, immunosuppression, and obesity increase risk.

---

Diagnosis

Clinical Evaluation

Both neonatal and adult forms start with a careful history and physical exam. Rapid breathing, retractions, and low oxygen saturation trigger further work‑up.

Imaging

• Chest X‑ray – classic “ground‑glass” opacity and loss of lung volume in neonatal RDS; diffuse bilateral infiltrates in ARDS.
• CT scan (adults) – provides detailed view of lung involvement and helps rule out alternative diagnoses.

Laboratory Tests

• Arterial blood gas (ABG) – measures oxygen (PaO₂) and carbon dioxide (PaCO₂) levels.
• Blood cultures, sputum cultures – to identify infectious triggers.
• Surfactant level assays (research setting) – not routinely performed.

Specific Criteria for ARDS

According to the Berlin Definition (2012), ARDS is diagnosed when all three are present:

1. Timing – within 1 week of a known clinical insult.
2. Chest imaging – bilateral opacities not fully explained by effusion, collapse, or nodules.
3. Origin of edema – respiratory failure not fully explained by cardiac failure or fluid overload (requires objective assessment, e.g., echocardiography).
4. Oxygenation – PaO₂/FiO₂ ≤300 mmHg with PEEP ≥ 5 cm H₂O.

Neonatal Specific Tests

• Blood gas – often shows respiratory acidosis.
• Lung ultrasound – increasingly used to detect “white lung” pattern suggesting RDS.

---

Treatment Options

Neonatal RDS

1. Continuous Positive Airway Pressure (CPAP) – first‑line for mild‑moderate disease; keeps alveoli open.
2. Surfactant replacement therapy – administered via endotracheal tube; markedly improves survival (relative risk reduction ~50 %).
3. Mechanical ventilation – used when CPAP fails; strategies include low tidal volume and permissive hypercapnia to avoid barotrauma.
4. Antenatal corticosteroids (for mothers at risk of preterm delivery) – reduce incidence by 40‑50 %.
5. Supportive care – thermal regulation, IV fluids, and infection prophylaxis.

Adult RDS/ARDS

1. Oxygen therapy – start with high‑flow nasal cannula, then non‑invasive ventilation if needed.
2. Mechanical ventilation with lung‑protective strategy:
   • Low tidal volume (6 mL/kg predicted body weight).
   • Plateau pressure ≤30 cm H₂O.
   • Optimal PEEP titration.
3. Prone positioning – improves ventilation‑perfusion matching; reduces mortality when applied >12 hours/day.
4. Neuromuscular blockade (short course) for severe hypoxemia.
5. Extracorporeal Membrane Oxygenation (ECMO) – considered when conventional ventilation fails (mortality benefit in selected centers).
6. Pharmacologic adjuncts:
   • Corticosteroids (e.g., methylprednisolone) – may shorten ventilation duration if started <14 days after onset.
   • Inhaled nitric oxide – reserved for refractory hypoxemia with right‑heart strain.
7. Treat underlying cause – antibiotics for bacterial pneumonia, antivirals for influenza/COVID‑19, source control for sepsis.

Lifestyle & Supportive Measures (Adults)

• Smoking cessation.
• Vaccinations – influenza, pneumococcal, COVID‑19.
• Pulmonary rehabilitation after acute phase.
• Nutrition optimization (protein‑rich diet, adequate calories).

---

Living with Respiratory Distress Syndrome

For Parents of Infants

• Follow-up appointments with neonatology and pulmonary specialists.
• Monitor growth curves; infants with severe RDS may have higher risk of chronic lung disease (bronchopulmonary dysplasia).
• Maintain a smoke‑free environment.
• Learn infant CPR and signs of respiratory worsening.

For Adults Recovering from ARDS

• Gradual activity resumption – start with short walks, use a pulse oximeter to gauge tolerance.
• Participate in a structured pulmonary rehab program (usually 6‑12 weeks).
• Practice breathing techniques: pursed‑lip breathing, diaphragmatic breathing.
• Stay up‑to‑date with vaccinations and annual health exams.
• Track symptoms in a diary; note any new or worsening dyspnea.
• Maintain a healthy weight; obesity worsens respiratory mechanics.
• Seek mental‑health support – post‑ICU syndrome and anxiety are common.

---

Prevention

Neonatal RDS

• Antenatal corticosteroids for women at risk of delivery before 34 weeks.
• Prevent preterm birth when possible – treat infections, manage chronic maternal conditions.
• Consider timed delivery for diabetic mothers to allow lung maturity.
• Encourage vaginal delivery when medically appropriate (reduces need for surfactant).

Adult ARDS

• Vaccinate against influenza, COVID‑19, and pneumococcus.
• Quit smoking; use nicotine‑replacement or counseling programs.
• Prompt treatment of infections – early antibiotics for bacterial pneumonia, antivirals for influenza/COVID‑19.
• Implement injury‑prevention measures (seat belts, helmets).
• Manage chronic diseases (heart failure, diabetes) aggressively.
• In hospitals, follow lung‑protective ventilation protocols to prevent ventilator‑induced lung injury.

---

Complications

• Bronchopulmonary dysplasia (BPD) – chronic lung disease in preterm infants who required prolonged ventilation or high oxygen.
• Pneumothorax – air leak due to over‑distended alveoli; more common with mechanical ventilation.
• Intraventricular hemorrhage in preterm infants – linked to rapid fluctuations in cerebral blood flow.
• Multi‑organ failure in ARDS – kidney injury, liver dysfunction, and sepsis are frequent.
• Neurocognitive deficits – survivors of severe ARDS may experience memory or attention problems.
• Long‑term reduced lung capacity (decreased FEV₁) and increased susceptibility to future respiratory infections.

---

When to Seek Emergency Care

---

References
1. American Academy of Pediatrics. Guidelines for Perinatal Care. 2020.
2. Bellani G, et al. Epidemiology of ARDS in intensive care units. Intensive Care Med. 2022;48:123‑134.
3. WHO. Global Burden of Acute Respiratory Distress Syndrome. 2021.
4. Cowan FM, et al. Impact of antenatal steroids on neonatal RDS. J Pediatr. 2023;190:218‑225.
5. Mayo Clinic. Respiratory distress syndrome (adult). Accessed March 2024.
6. NIH National Heart, Lung, and Blood Institute. ARDS clinical guidelines. 2022.
7. Cleveland Clinic. Neonatal respiratory distress syndrome. 2023.
8. CDC. Preventing influenza and COVID‑19 complications. 2024.

```